TP53RK and neoplasm: By utilizing a CRISPR/Cas9-mediated epidermal-specific knockout mouse model and in vitro cell-based studies, we demonstrate that PRPK deficiency leads to significant suppression of tumor growth and reprogramming of the TME to favor antitumor immunity.